Global sales of Copaxone (20 mg/mL and 40 mg/mL), the leading multiple sclerosis therapy in the U.S. and globally, increased 1% compared to the first quarter of 2013. In the United States, sales increased 1% to $816 million following a price increase in January 2014. Sales outside the United States amounted to $254 million, a decrease of 2% in both U.S. dollar and local currency terms, compared to the first quarter of 2013. The decrease reflects the timing of tenders in Russia, which took place in the first quarter of 2013 but not in the first quarter of 2014, and was partially offset by higher sales in Europe.

As of April 18, 2014, Copaxone 40 mg/mL U.S. market share in terms of total prescriptions was 10.5%. Our U.S. market share for the two Copaxone products in terms of total prescriptions was 33.5%, with Copaxone 40 mg/mL then accounting for 31% of total Copaxone prescriptions.